Prices of Branded Medicines

1. At a Glance

• Drug pricing in India is regulated by the National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, via the Drugs (Prices Control) Order, 2013 (DPCO, 2013) rooted in the National Pharmaceuticals Pricing Policy, 2012 (NPPP-2012) [S1][S5].
• Pricing follows "essentiality + market-based" principles — ceiling prices are fixed only for formulations listed in Schedule-I of DPCO, which mirrors the National List of Essential Medicines (NLEM) [S1][S3].
• Relevant for UPSC: intersection of health policy, consumer welfare, IPR/industry competitiveness, and federal regulation (GS-II governance + GS-III economy).

2. Why in the News

• PIB release (6 Feb 2026) by DoP reiterated that the Department does not maintain cost data of companies and reaffirmed the market-based pricing framework of DPCO 2013 — responding to parliamentary scrutiny over high prices of branded (non-scheduled) medicines [S1].
• NPPA savings update (2025): average price reduction of ~17% under NLEM-2022 fixations yielded estimated ₹3,788 crore annual savings to patients [S3].

3. Background & Evolution

• 1970: First DPCO under the Essential Commodities Act, 1955 — cost-plus pricing.
• 1979, 1987, 1995: Successive DPCOs progressively reduced span of price control.
• 2012: National Pharmaceuticals Pricing Policy shifted basis from cost-based to market-based pricing [S1].
• 2013: DPCO 2013 notified — ceiling prices for Schedule-I formulations based on simple average of MRP of brands with ≥1% market share [S1].
• July 2014: NPPA invoked Para 19 (extraordinary powers) to cap prices of 106 anti-diabetic/cardiovascular formulations [S2].
• 2017: Coronary stents brought under price control; 2017: knee implants capped via Para 19 [S2].
• 2019: Trade Margin Rationalisation (TMR) introduced — cap on 42 non-scheduled anti-cancer drugs → MRP cut up to 90% across 526 brands [S2].
• Sept 2022: NLEM-2022 released listing 384 medicines across 27 therapeutic categories (34 added, 26 dropped) [S4].

4. Core Static Facts

• Regulator: National Pharmaceutical Pricing Authority (NPPA), an attached office of DoP, established 29 August 1997 [S1][S5].
• Parent Ministry: Ministry of Chemicals & Fertilizers → Department of Pharmaceuticals [S1].
• Enabling legal framework: DPCO 2013 issued under Section 3 of the Essential Commodities Act, 1955 [S1].
• Schedule-I of DPCO 2013 = list of price-controlled formulations, aligned with NLEM [S1].
• NLEM-2022: 384 essential medicines [S4].
• Ceiling price formula (Para 4, DPCO 2013): simple average of MRP of all brands of that drug having market share ≥ 1%, + notional retailer margin of 16% [S1].
• Annual revision: scheduled-drug ceiling prices revised by WPI (Wholesale Price Index); non-scheduled drugs allowed max 10% MRP increase per year [S5].
• Para 19 DPCO 2013: "Extraordinary powers" — Government can fix prices of any drug in public interest [S2].
• Coverage as on 12.03.2025: ceiling prices of 928 scheduled formulations + retail prices of >3,200 new drugs fixed by NPPA [S3].
• MRP disclosure: mandatory for every formulation (scheduled + non-scheduled) on label of container & minimum pack [S1].
• Janaushadhi (PMBJP): generic medicines at Jan Aushadhi Kendras priced 50–80% below branded equivalents [S3].

5. Multi-Dimensional Analysis

Economic - Pricing balances affordability vs. industry profitability — DoP explicitly cites supporting innovation and competition as a co-objective [S1]. - TMR on anti-cancer drugs cut MRP up to 90% without disrupting supply, suggesting margin (not cost) drives high branded prices [S2]. - Estimated ₹3,788 cr/year consumer saving under NLEM-2022 fixations [S3].

Social / Welfare - ~62% of health expenditure in India is out-of-pocket; medicines form the largest share — making price control a poverty-prevention tool (contextual). - Branded-generic price spreads of 5×–20× persist for non-scheduled drugs because only NLEM molecules are capped [S1][S3].

Legal / Constitutional - DPCO is subordinate legislation under Essential Commodities Act, 1955 — invocable on grounds of "public interest" [S1]. - Para 19 functions as residual regulatory power — used for stents, knee implants, anti-cancer drugs, COVID-19 devices [S2].

Administrative / Governance - DoP does not maintain company cost data — pure market-based methodology limits ability to challenge MRP build-up [S1]. - Implementation split: NPPA fixes price; State Drug Controllers enforce overcharging recovery; CDSCO handles quality/efficacy.

Ethical - Tension between TRIPS-compliant patent regime (high innovator prices) and right to health (Art. 21 jurisprudence — Paschim Banga Khet Mazdoor Samity). - Cost-plus → market-based shift reduced regulatory friction but widened gap between branded and generic prices, raising equity concerns.

6. Recent Developments (last 12–18 months)

• Feb 2026 (PIB): DoP clarification that cost data is not maintained; pricing remains market-based [S1].
• 2025 NPPA update: 928 scheduled formulations capped; ~17% average price reduction; ₹3,788 cr annual patient savings [S3].
• 2025: NPPA continued fixing retail prices of new drugs under Para 15 (>3,200 cumulative) [S3].
• Trade-margin approach extended to medical devices (oximeters, oxygen concentrators) during COVID-19 [S2].

7. Prelims Hooks

• DPCO 2013 is issued under Section 3 of Essential Commodities Act, 1955 — NOT under the Drugs & Cosmetics Act [S1].
• NPPA established in 1997; attached office of Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) [S1].
• NLEM-2022 contains 384 medicines in 27 therapeutic categories [S4].
• Schedule-I of DPCO 2013 = price-controlled formulations list (mirrors NLEM) [S1].
• Ceiling price formula uses brands with ≥ 1% market share; retailer margin notionally 16% [S1].
• Non-scheduled drugs: max 10% MRP hike per year permitted [S5].
• Scheduled-drug ceilings revised by WPI annually [S5].
• Para 19 DPCO 2013 = "extraordinary powers in public interest" — used for stents (2017), knee implants (2017), anti-cancer drugs (2019) [S2].
• TMR on 42 anti-cancer non-scheduled drugs reduced MRP up to 90% across 526 brands [S2].
• PMBJP medicines priced 50–80% below branded equivalents [S3].
• NLEM-2022 led to ~17% avg price reduction and ₹3,788 cr/year savings [S3].
• As on 12 Mar 2025: NPPA had fixed prices of 928 scheduled formulations + >3,200 new drugs [S3].

8. Mains Relevance

• GS-II: Government policies and interventions for development in social sector (Health); Issues relating to development and management of Health.
• GS-III: Indian economy — Inclusive growth; Issues of pricing and consumer welfare.
• Plausible question stems: 1. "Market-based pricing under DPCO 2013 has reduced essential-drug prices but failed to rein in branded-generic disparity." Critically examine. 2. Discuss the role of NPPA in ensuring affordable access to medicines. How effective has the Trade Margin Rationalisation approach been? 3. Examine whether India's pharmaceutical pricing framework adequately balances affordability with innovation incentives.

9. Related Topics to Study Next

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — generic-medicine retail network complements price control.
• Indian Patents Act 1970 & Section 3(d) / Compulsory Licensing — IPR pillar of drug affordability.
• CDSCO & Drugs and Cosmetics Act, 1940 — quality vs. price (twin regulatory pillars).
• Ayushman Bharat PM-JAY — demand-side insurance complements supply-side price control.
• Production Linked Incentive (PLI) for Pharma / Bulk Drugs Parks — supply security & API self-reliance.
• WHO Model List of Essential Medicines — global benchmark for NLEM.
• TRIPS Agreement & Doha Declaration on Public Health — geopolitical context.
• National Medical Devices Policy, 2023 — extending price regulation to devices.

10. Common Errors / Trap Areas

• NPPA is under Department of Pharmaceuticals (Min. of Chemicals & Fertilizers) — NOT under Ministry of Health & Family Welfare; NLEM, however, is prepared by MoHFW.
• DPCO 2013 derives authority from Essential Commodities Act, 1955, not the Drugs & Cosmetics Act, 1940.
• Price control is only for Schedule-I (NLEM-linked) formulations — most "branded" drugs are non-scheduled and only subject to 10% annual cap and disclosure norms.
• NLEM-2022 = 384 drugs, not 870 or "all branded drugs."
• Trade Margin Rationalisation ≠ ceiling-price fixation; it caps the margin between Price-to-Stockist and MRP, used for non-scheduled drugs/devices.
• DPCO 2013 uses market-based (not cost-based) pricing — Department does not collect company cost data.

11. Sources

• [S1] Prices of Branded Medicines — PIB, DoP, 06 Feb 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224372 — (tier: 1)
• [S2] NPPA — Trade Margin Rationalisation on anti-cancer medicines — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1744388 — (tier: 1)
• [S3] NLEM-2022 savings ₹3,788 cr; 928 formulations; PMBJP 50–80% — PIB — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2112308 — (tier: 1)
• [S4] Launch of NLEM-2022 (384 medicines, 27 categories) — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1858931 — (tier: 1)
• [S5] NPPA fixes ceiling prices under Schedule-I DPCO 2013 — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2100720 — (tier: 1)